Channel Robotics Raises $4.6M for Endoscopic Robotics

Channel Robotics, a San Diego-based innovator in medical robotics, has successfully secured a total of $4.6 million in funding to propel its novel handheld endoscopic robotics platform. This infusion of capital is earmarked for significant advancements in product development, navigating regulatory pathways, and preparing for market entry.

The latest funding push includes a $2.5 million Seed+ round spearheaded by True Ventures. This follows an earlier $2.1 million seed financing, which saw participation from notable investors including Defined VC and Old Line Capital Partners. The combined financial backing underscores strong investor confidence in the company's vision to reshape endoscopic procedures.

At the heart of Channel Robotics' innovation is a patented, handheld robotic system designed to integrate seamlessly with existing flexible endoscopes. The technology aims to provide robotic-level precision and maneuverability, a significant departure from the bulky, expensive systems currently dominating the market. This approach promises to democratize access to advanced minimally invasive interventions, making them feasible in a wider array of clinical settings, from major hospitals to smaller outpatient centers.

The medical robotics market is experiencing robust growth, driven by an increasing demand for less invasive procedures and improved patient outcomes. The global market for surgical robotics alone is projected to reach tens of billions of dollars in the coming years. Channel Robotics' strategy to leverage existing infrastructure rather than requiring entirely new capital investments positions it to capture a substantial share of this expanding sector, particularly in the flexible endoscopy segment which is critical for diagnostics and treatment in gastroenterology, pulmonology, and urology.

Funds from this financing will be strategically allocated to further refine and validate the prototype platform, bolster engineering and product development teams, and meticulously prepare for a targeted FDA submission in 2027. Additionally, resources will support the establishment of robust manufacturing and quality control systems, crucial steps in readiness for a commercial launch post-regulatory clearance. The company, co-founded by physician-scientist Philip Weissbrod and roboticist Michael Yip, emphasizes scalable solutions that fit within current clinical workflows.

“Our objective is to make sophisticated endoscopic robotics accessible to a broader physician base,” stated Michael Yip, Co-Founder of Channel Robotics. “This funding empowers us to develop a practical, scalable, and cost-effective platform that brings advanced robotic capabilities directly to clinicians.” Philip Weissbrod, Co-Founder and CEO, added, “With the backing of True Ventures and our existing investors, we are accelerating our development to deliver technology that is easier to adopt and can benefit a greater number of patients.”

Rohit Sharma, Partner at True Ventures, commented on the investment, highlighting the founders' unique blend of clinical insight and robotics expertise. “Their innovation addresses significant challenges in robotic surgery, ultimately serving human health. We are proud to support their journey in creating practical solutions for a vast number of clinics and physicians.” This strategic investment is set to accelerate Channel Robotics' mission to redefine the future of endoscopic interventions.